The epidemiological contribution to the preparation of field trials for HIV and STI vaccines: Objectives and methods of feasibility studies

Vaccine

Volumn 23, Issue 12, 2005, Pages 1437-1445

  Suligoi, Barbara ^a   Wagner, Theresa M ^b   Ciccozzi, Massimo ^a   Rezza, Giovanni ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b HIV Research Section   (United States)

Author keywords

Epidemiology; HIV; HPV; HSV; Prevention; STD; STI; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACCURACY; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FOLLOW UP; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMED CONSENT; PRIORITY JOURNAL; RISK REDUCTION; SEXUALLY TRANSMITTED DISEASE;

AIDS VACCINES; FEASIBILITY STUDIES; HIV INFECTIONS; HUMANS; SEXUALLY TRANSMITTED DISEASES; VIRAL VACCINES;

EID: 12844266865     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.10.002     Document Type: Article

References (80)

1. S.H. Vermund Vaccine efficacy trials for human immunodeficiency virus/acquired immunodeficiency syndrome are feasible in the United States: a commentary on the HIVNET vaccine preparedness study Am J Epidemiol 153 2001 628 631
2. A.R. Sheon Overview: HIV vaccine feasibility studies AIDS Res Hum Retroviruses 10 Suppl 2 1994 S195 S196
3. W.L. Heyward, S. Osmanov, and J. Esparza Preparing for HIV vaccine efficacy trials in developing countries J.M. Mann DJ.M. Tarantola AIDS in the World II 1996 Oxford University Press New York and Oxford 193 195
4. W.L. Heyward, S. Osmanov, J. Saba, J. Esparza, E. Belsey, and R. Stoneburner Preparation for phase III HIV vaccine efficacy trials: methods for the determination of HIV incidence AIDS 8 1994 1285 1291
5. J.M. Baeten, B.A. Richardson, H.L. Martin, P.M. Nyange, L. Lavreys, and E.N. Ngugi Trends in HIV incidence in a cohort of prostitutes in Kenya: implications for HIV-vaccine efficacy trials JAIDS 24 2000 458 464
6. R.S. Janssen, G.A. Satten, S.L. Stramer, B.D. Rawal, T.R. O'Brien, and B.J. Weiblen New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes J Am Med Assoc 280 1998 42 48
7. B. Suligoi, C. Galli, M. Massi, F. Di Sora, M. Sciandra, and P. Pezzotti The precision and accuracy of a procedure for detecting recent HIV infections, calculating the antibody avidity index using an automated immunoassay J Clin Microbiol 40 2002 4015 4020
8. T. Dobbs, S. Kennedy, C.P. Pau, J.S. McDougal, and B.S. Parekh Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion Clin Microbiol 42 6 2004 2623 2628
9. M. Peeters, and P.M. Sharp Genetic diversity of HIV-1: the moving target AIDS 14 Suppl 2000 S129 S140
10. P. Lurie, M. Bishaw, M.A. Chesney, M. Cooke, M.E. Fernandes, and N. Hearst Ethical, behavioural, and social aspects of HIV vaccine trials in developing countries J Am Med Assoc 271 1994 295 301
11. C. Harro, F. Judson, S.J. Brown, M. Marmor, E. Li, and G. Alonzo Successful recruitment and conduct of the first HIV vaccine efficacy trial in North America and Europe Proceedings of the the XIII International AIDS Conference ##### 2000 Abstract WeOrC556
12. E. Gouws, Q. Abdool Karim, J. Frohlich, and S. Abdool Karim Preparing for Phase III HIV vaccine trials: experiences from rural South Africa Proceedings of the the XIII International AIDS Conference ##### 2000 Abstract ThOrD678
13. E. Mugisha, P. Mugyenyi, R. Byaruhanga, C. Turyatemba, D. Akurut, and M. Achom Clinical trials and community participation perspectives in HIV/AIDS research programs in Uganda Proceedings of the the XIII International AIDS Conference ##### 2000 Abstract ThPeD5669
14. UNAIDS guidance document: ethical considerations in HIV preventive vaccine research. Joint United Nations Programme on HIV/AIDS, Geneva. 2000 (Document UNAIDS/00.07E).
15. W. Szmuness Large-scale efficacy trials of hepatitis B vaccines in the USA: baseline data and protocols J Med Virol 4 1979 327 340
16. B.N. Bartholow, K.M. MacQueen, J.M. Douglas Jr., S. Buchbinder, D. McKirnan, and F.N. Judson Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men J Acquir Immune Defic Syndr Hum Retrovirol 16 1997 108 115
17. B.A. Koblin, S. Holte, B. Lenderking, and P. Heagerty Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET Vaccine Preparedness Study Protocol Team J Acquir Immune Defic Syndr 24 2000 451 457
18. S.D. Halpern, D.S. Metzger, J.A. Berlin, and P.A. Ubel Who will enroll? Predicting participation in a phase II AIDS vaccine trial JAIDS 17 2001 281 288
19. S.P. Buchbinder, B. Metch, S. Holte, S. Scheer, A. Coletti, and E. Vittinghoff Determinants of enrollment in a preventive HIV vaccine Trial. Hypothetical versus actual willingness and barriers to participation JAIDS 36 2004 604 612
20. L.R. Temoshok Behavioural research contributions to planning and conducting HIV vaccine efficacy studies AIDS Res Hum Retroviruses 10 Suppl 2 1994 S277 S280
21. B.A. Koblin, P. Heagerty, A. Sheon, S. Buchbinder, C. Celum, and J.M. Douglas Readiness of high-risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States AIDS 12 1998 785 793
22. on behalf of the COL 1492 Study Group G. Ramjee, N.S. Morar, M. Alary, L. Mukenge-Tshibaka, B. Vuylsteke, and V. Ettiègne-Traoré Challenges in the conduct of vaginal microbicide effectiveness trials in the developing world AIDS 14 2000 2553 2557
23. M.P. Preziosi, A. Yam, M. Ndiaye, A. Simaga, F. Simondon, and SG.F. Wassilak Pratical experiences in obtaining informed consent for a vaccine trial in rural Africa N Engl J Med 336 1997 370 372
24. G. Lindegger, and L. Richter Cross-cultural issues in the implementation of informed consent in HIV vaccine trials in South Africa Proceedings of the the XIII International AIDS Conference ##### 2000 Abstract ThOrE652
25. C.F. Turner, and A.R. Sheon Efficacy trials preparations colloquium IV(B) Methodology panel on behavioural studies relevant to vaccine trials preparation AIDS Res Hum Retroviruses 10 Suppl 2 1994 S273 S276
26. D.S. Metzger, B. Koblin, C. Turner, H. Navaline, F. Valenti, and S. Holte Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team Am J Epidemiol 152 2000 99 106
27. G.D. Zimat, M.J. Blythe, and J.D. Fortenberry Vaccine characteristics and acceptability of HIV immunization among adolescents Int J STD AIDS 11 2000 143 149
28. S. Forsythe, G. Arthur, R. Mutemi, and C. Gilks The economics of an AIDS vaccine in Kenya Proceedings of the the XIII International AIDS Conference ##### 2000 Abstract MoOrC127
29. J.L. Excler, and C. Beyrer Human immunodeficiency virus vaccine development in developing countries: are efficacy trials feasible? J Hum Virol 3 2000 193 214
30. M. McCarthy HIV vaccine fails in phase 3 trial Lancet 361 2003 755 756
31. J. Cohen Thailand beats the odds in completing vaccine test Science 301 2003 1663
32. C. Trinvuthipong Thailand's prime-boost HIV vaccine phase III Science 303 2004 954 955
33. S.H. Vermund Vaccine efficacy trials for human immunodefiency virus/acquired immunodeficiency syndrome are feasible in the United States: a commentary on the HIVNET Vaccine Preparedness Study Am J Epidemiol 153 2001 628 631
34. S.P. Buchbinder, J.M. Douglas Jr., and D.J. McKirnan Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behaviour, seroincidence, and willingness to participate J Infect Dis 174 1996 954 961
35. S. Scheer, J.M. Douglas Jr., E. Vittinghoff, B.N. Bartholow, D. McKiman, and L.H. Harrison Feasibility and suitability of targeting young gay men for HIV vaccine efficacy trials J Acquir Immune Defic Syndr Hum Retrovirol 20 1999 172 178
36. Projeto Praco Onze Study Group A. Perisse, M. Schechter, R. Moreira, R.F. do Lago, G. Santoro-Lopes, and L.H. Harrison Willingness to participate in HIV vaccine trials among men who have sex with men in Rio de Janeiro, Brazil JAIDS 25 2000 459 463
37. G. Serpelloni, D. Vlahov, M. Mazzi, and G. Rezza Interest in HIV vaccine among Italian injection drug users J Acquir Immune Defic Syndr 10 1995 206 207
38. D.D. Celentano, C. Beyrer, C. Natpratan, S. Eiumtrakul, L. Sussman, and P.O. Renzullo Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand AIDS 9 1995 1079 1083
39. K. Moodley, J. Barnes, E.J. van Rensburg, and L. Myer Willingness to participate in South African HIV vaccine trials - concerns of medical professionals in the Western Cape S Afr Med J 92 2002 904 906
40. S. Vanichseni, J.W. Tappero, P. Pitisuttithum, D. Kitayaporn, T.D. Mastro, and E. Vimutisunthorn Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand AIDS 18 2004 311 316
41. G.R. Seage, S.E. Holte, D. Metzger, B.A. Kobiin, M. Gross, and C. Celum Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study Am J Epidemiol 153 2001 619 627
42. M. Marmor, S. Titus, H. Wolfe, K. Krasinski, R. Maslansky, and M. Simberkoff Preparations for AIDS vaccine trials. Retention, behaviour change, and HIV-seroconversion among injecting drug users (IDUs) and sexual partners of IDUs AIDS Res Hum Retroviruses 10 S2 1994 S207 S213
43. K. Harrison, D. Vlahov, K. Jones, K. Charron, and M.L. Clements Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial Acquir Immune Defic Syndr Hum Retrovirol 10 1995 386 390
44. C. Natpratan, D. Nantakwang, C. Beyrer, P. Kunawararak, C. Gunnom, and D.D. Ceientario Feasibility of northern Thai factory workers as participants in HIV vaccine trials Southeast Asian J Trop Med Public Health 27 1996 457 462
45. K.E. Nelson, C. Beyrer, C. Natpratan, S. Eiumtrakul, D.D. Celentano, and C. Khamboonruang Preparatory studies for possible HIV vaccine trials in northern Thailand AIDS Res Hum Retroviruses 10S2 1994 S243 S246
46. F. Magusi, R. Josiah, A. Moshi, S. Chale, M. Bakari, and E. Aris Dropouts in a long-term follow-up study involving voluntary counselling and HIV testing: experience from a cohort of police officers in Dar es Salaam, Tanzania J Acquir Immune Defic Syndr 30 2002 119 123
47. M. Carneiro, C.M. de Figueiredo Antunes, M. Greco, E. Oliveira, J. Andrade, and L. Lignani Jr. Design, implementation, and evaluation at entry of a prospective cohort of homosexual and bisexual HIV-1-negative men in Belo Horizonte, Brazil: Project Horizonte J Acquir Immune Defic Syndr 25 2000 182 187
48. S. Vanichseni, D. Kitayapora, T.D. Mastro, P.A. Mock, S. Raktham, and D.C. Des Jarlais Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand AIDS 15 2001 397 405
49. L.E. Markowitz, N. Sirisopana, A. Charonwatanachokchai, W. Julvanlchpong, T. Siraprapasiri, and T. Palanuvej Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand J Acquir Defic Syndr Hum Retrovirol 20 1999 488 494
50. B.A. Koblin, P.E. Taylor, S. Avrett, and C.E. Steven The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New YorkCity: project ACHIEVE. AIDS Community Health Initiative Enroute to the Vaccine Effort AIDS 10 1996 1555 1561
51. W. Szmuness, I. Much, A.M. Prince, J.H. Hoofnagle, C.E. Cherubin, and E.J. Harley On the role of sexual behaviour in the spread of hepatitis B infection Ann Intern Med 83 1975 489 495
52. A. Wald, J. Zeh, S. Selke, R.L. Ashley, and L. Corey Virologic characteristics of subclinical and symptomatic genital herpes infections N Engl J Med 333 1995 770 775
53. L.R. Stanberry, A.L. Cunningham, A. Mindel, L.L. Scott, S.L. Spruance, and F.Y. Aoki Prospects for control of herpes simplex virus disease through immunization Clin Infect Dis 30 2000 549 566
54. GlaxoSmithKline Herpes Vaccine Efficacy Study Group L.R. Stanberry, S.L. Spruance, A.L. Cunningham, D.I. Bernstein, A. Mindel, and S. Sacks Glycoprotein-d-adjuvant vaccine to prevent genital herpes N Engl J Med 347 2002 1652 1661
55. A.J. Vyse, N.J. Gay, M.J. Slomka, R. Gopal, T. Gibbs, and P. Morgan-Capner The burden of infection with HSV-1 and HSV-2 in England and Wales: implications for the changing epidemiology of genital herpes Sex Transm Infect 76 2000 183 187
56. A. Wald, and K. Link Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis J Infect Dis 185 2002 45 52
57. C.L. Celum The interaction between herpes simplex virus and human immunodeficiency virus Herpes 11 Suppl 1 2004 36A 45A
58. A. Wald, D. Carrell, M. Remington, E. Kexel, J. Zeh, and L. Corey Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection Clin Infect Dis 34 2002 944 948 Epub 2002 Feb 20
59. D.H. Watts, Z.A. Brown, D. Money, S. Selke, M.L. Huang, and S.L. Sacks A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery Am J Obstet Gynecol 188 2003 836 843
60. Valacyclovir HSV Transmission Study Group L. Corey, A. Wald, R. Patel, S.L. Sacks, S.K. Tyring, and T. Warren Once-daily valacyclovir to reduce the risk of transmission of genital herpes N Engl J Med 350 2004 11 20
61. Z.A. Brown, S. Selke, J. Zeh, J. Kopelman, A. Maslow, and R.L. Ashley The acquisition of Herpes simplex virus during pregnancy New Engl J Med 337 1997 509 515
62. L.M. Lewis, L.R. Stanberry, S.L. Rosenthal, D.A. Stewart, P.A. Succop, and D.I. Bernstein Attitudes regarding vaccinations of STDs and other diseases Int J STD AIDS 11 2000 170 172
63. International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group J.S. Smith, R. Herrero, C. Bosetti, N. Munoz, F.X. Bosch, and J. Eluf-Neto Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer J Natl Cancer Inst 6 94 2002 1604 1613
64. Koutsky LA, Kiviat NB. Genital human papillomavirus. In: Holmes K, et al., editors. Sexually transmitted diseases, 3rd edition. New York, McGraw-Hill, 1999.
65. C.B. Woodman, S. Collins, H. Winter, A. Bailey, J. Ellis, and P. Prior Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study Lancet 357 2001 1831 1836
66. R.D. Burk, G.Y. Ho, L. Beardsley, M. Lempa, M. Peters, and R. Bierman Sexual behaviour and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women J Infect Dis 174 1996 679
67. K.L. Wallin, F. Wiklund, T. Angstrom, F. Bergman, U. Stendahl, and G. Wadell Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer N Engl J Med 341 1999 1633 1638
68. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Monographs on the evaluation of carcinogenic risks to humans. Vol. 64, Human Papillomaviruses. Lyon, IARC, 1995: p. 1-409.
69. J. Paavonen, M. Halttunen, B.G. Hansson, P. Nieminen, T. Rostila, and M. Lehtinen Prerequisites for human papillomavirus vaccine trial: results of feasibility studies J Clin Virol 19 2000 25 30
70. G.Y. Ho, Y. Studentsov, C.B. Hall, R. Bierman, L. Beardsley, and M. Lempa Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles J Infect Dis 186 2002 737 742
71. K. Kawana, T. Yasugi, T. Kanda, Y. Kawana, Y. Hirai, and H. Yoshikawa Neutralizing antibodies against oncogenic human papillomavirus as a possible determinant of the fate of low-grade cervical intraepithelial neoplasia Biochem Biophys Res Commun 296 2002 102 105
72. E. Sigstad, A.K. Lie, T. Luostarinen, J. Dillner, E. Jellum, and M. Lehtinen A prospective study of the relationship between prediagnostic human papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas Br J Cancer 87 2002 175 180
73. E. Lazcano-Ponce, L. Rivera, E. Arillo-Santillan, J. Salmeron, M. Hernandez-Avila, and N. Munoz Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca Mexico Arch Med Res 32 2001 243 247
74. D.R. Hoover, B. Carfioli, and E.A. Moench Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials Health Care Women Int 21 2000 375 391
75. L.A. Koutsky, K.A. Ault, C.M. Wheeler, D.R. Brown, E. Barr, and F.B. Alvarez A controlled trial of a human papillomavirus type 16 vaccine N Engl J Med 347 2002 1645 1651
76. K.H. Fife, C.M. Wheeler, L.A. Koutsky, E. Barr, D.R. Brown, and M.A. Schiff Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women Vaccine 22 21/22 2004 2943 2952
77. D.R. Brown, K.H. Fife, C.M. Wheeler, L.A. Koutsky, L.M. Lupinacci, and R. Railkar Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine Vaccine 22 21/22 2004 2936 2942
78. E.J. Davidson, C.M. Boswell, P. Sehr, M. Pawlita, A.E. Tomlinson, and R.J. McVey Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins Cancer Res 63 18 2003 6032 6041
79. M. Reinis Technology evaluation: HPV vaccine (quadrivalent), Aventis Pasteur MSD/CSL Curr Opin Mol Ther 6 2004 206 211
80. S. Hallez, P. Simon, F. Maudoux, J. Doyen, J.C. Noel, and A. Beliard Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia Cancer Immunol Immunother 53 7 2004 642 650 Epub 2004, February 17